Eastern Asia: Medicaments Containing Insulin Market 2024

Medicaments Containing Insulin Market Size in Eastern Asia

In 2023, after three years of growth, there was significant decline in the East Asian medicaments containing insulin market, when its value decreased by X% to $X. Overall, consumption, however, showed a resilient increase. The level of consumption peaked at $X in 2022, and then declined rapidly in the following year.

Medicaments Containing Insulin Production in Eastern Asia

In value terms, medicaments containing insulin production expanded modestly to $X in 2023 estimated in export price. Overall, production, however, saw a buoyant expansion. The most prominent rate of growth was recorded in 2017 when the production volume increased by X% against the previous year. The level of production peaked at $X in 2021; however, from 2022 to 2023, production failed to regain momentum.

Medicaments Containing Insulin Exports

Exports in Eastern Asia

For the third consecutive year, Eastern Asia recorded growth in overseas shipments of medicaments containing insulin but not antibiotics, which increased by X% to X tons in 2023. Overall, exports recorded a significant increase. The pace of growth appeared the most rapid in 2021 with an increase of X%. Over the period under review, the exports hit record highs in 2023 and are likely to see gradual growth in years to come.

In value terms, medicaments containing insulin exports fell to $X in 2023. In general, exports posted prominent growth. The pace of growth appeared the most rapid in 2021 when exports increased by X% against the previous year. The level of export peaked at $X in 2022, and then dropped in the following year.

Exports by Country

In 2023, China (X tons) was the major exporter of medicaments containing insulin but not antibiotics, generating X% of total exports. It was distantly followed by Hong Kong SAR (X tons), committing a X% share of total exports.

China was also the fastest-growing in terms of the medicaments containing insulin but not antibiotics exports, with a CAGR of X% from 2012 to 2023. At the same time, Hong Kong SAR (X%) displayed positive paces of growth. While the share of China (X p.p.) and Hong Kong SAR (X p.p.) increased significantly, the shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, Hong Kong SAR ($X) remains the largest medicaments containing insulin supplier in Eastern Asia, comprising X% of total exports. The second position in the ranking was held by China ($X), with a X% share of total exports.

From 2012 to 2023, the average annual growth rate of value in Hong Kong SAR totaled X%.

Export Prices by Country

In 2023, the export price in Eastern Asia amounted to $X per ton, which is down by X% against the previous year. Overall, the export price recorded a abrupt setback. The most prominent rate of growth was recorded in 2016 an increase of X%. As a result, the export price reached the peak level of $X,333 per ton. From 2017 to 2023, the export prices failed to regain momentum.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was Hong Kong SAR ($X per ton), while China stood at $X per ton.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by Hong Kong SAR (X%).

Medicaments Containing Insulin Imports

Imports in Eastern Asia

Medicaments containing insulin imports skyrocketed to X kg in 2023, jumping by X% against the year before. In general, imports, however, showed a abrupt contraction. The pace of growth was the most pronounced in 2020 with an increase of X%. Over the period under review, imports attained the peak figure at X kg in 2015; however, from 2016 to 2023, imports failed to regain momentum.

In value terms, medicaments containing insulin imports surged to $X in 2023. Overall, imports, however, saw a perceptible contraction. The most prominent rate of growth was recorded in 2020 with an increase of X% against the previous year. As a result, imports attained the peak of $X. From 2021 to 2023, the growth of imports remained at a lower figure.

Imports by Country

Hong Kong SAR was the major importing country with an import of about X kg, which reached X% of total imports. Japan (X kg) ranks second in terms of the total imports with a X% share, followed by South Korea (X%). Taiwan (Chinese) (X kg) took a little share of total imports.

Imports into Hong Kong SAR decreased at an average annual rate of X% from 2012 to 2023. South Korea (X%), Japan (X%) and Taiwan (Chinese) (X%) illustrated a downward trend over the same period. While the share of Hong Kong SAR (X p.p.), Japan (X p.p.) and South Korea (X p.p.) increased significantly in terms of the total imports from 2012-2023, the share of Taiwan (Chinese) (X p.p.) displayed negative dynamics.

In value terms, Hong Kong SAR ($X), Japan ($X) and South Korea ($X) appeared to be the countries with the highest levels of imports in 2023, together accounting for X% of total imports.

South Korea, with a CAGR of X%, recorded the highest growth rate of the value of imports, among the main importing countries over the period under review, while purchases for the other leaders experienced a decline in the imports figures.

Import Prices by Country

In 2023, the import price in Eastern Asia amounted to $X per ton, increasing by X% against the previous year. Over the period under review, the import price recorded a buoyant expansion. The pace of growth appeared the most rapid in 2019 when the import price increased by X%. Over the period under review, import prices hit record highs at $X per ton in 2021; however, from 2022 to 2023, import prices failed to regain momentum.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was Taiwan (Chinese) ($X per ton), while Hong Kong SAR ($X per ton) was amongst the lowest.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by Taiwan (Chinese) (X%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform